AstraZeneca’s Farxiga reduces CV mortality risk in Phase III trials

AstraZeneca’s Farxiga reduces CV mortality risk in Phase III trials

Submitted by admin on August 29, 2022 - 11:01am
Source: 
Clinical Trials Arena
News Tags: 
AstraZeneca
Farxiga
clinical trials
heart failure
Headline: 
AstraZeneca’s Farxiga reduces CV mortality risk in Phase III trials
snippet: 

The Farxiga treatment offered a 10% and 29% reduction in death from any cause and total hospitalization for HF, respectively.

Do Not Allow Advertisers to Use My Personal information